Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
about
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health CentreTime-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in ratsUse pattern and off-label use of atypical antipsychotics in bipolar disorder, 1998-2002Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.Relationship of atypical antipsychotics with development of diabetes mellitus.Schizophrenia, the metabolic syndrome and diabetes.Atypical antipsychotics and diabetes mellitus.Metabolic effects associated with atypical antipsychotic medications.The role of atypical antipsychotics in glucose/insulin dysregulation and the evolving role of the psychiatrist in a new era of drug treatment options.Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans.Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?Pharmacological treatment strategies for schizophrenia.Mental health policy and psychotropic drugsA review of clozapine safety.Metabolic side effects of atypical antipsychotics in children: a literature review.Development and validation of an HPLC-UV method for the simultaneous determination of the antipsychotics clozapine, olanzapine and quetiapine, several beta-blockers and their metabolites.An overview of the central control of weight regulation and the effect of antipsychotic medication.The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?Association between antipsychotic drugs and diabetes.The metabolic effects of antipsychotic medications.Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.The effect of clozapine on factors controlling glucose homeostasisManagement of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness.Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, IranBlood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.Cardiovascular safety of antipsychotics: a clinical overview.Atypical antipsychotics: revolutionary or incremental advance?Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine.Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis.Efficacy should drive atypical antipsychotic treatmentResponse to regulatory stringency: the case of antipsychotic medication use in nursing homes.The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service.Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Clozapine-induced hypertension: A case report and review of literature.No change of the lipid profile under the control of ApoE gene polymorphism in schizophrenics under paliperidone treatment.Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years.Diabetic ketoacidosis and severe hypertriglyceridaemia as a consequence of an atypical antipsychotic agent.
P2860
Q33236751-6BC5A8FA-FDE5-498D-8CF3-DB51D5D1AA52Q33765864-67EB4927-3802-4C66-834F-D1B2A4A44BDCQ33932148-D0FFAE7D-7469-457D-A9F6-19D36CF9E472Q34595255-92348410-2F88-4F7A-85CA-99E0532953C4Q35591014-47EAF02C-AFC8-4DC2-BF2F-B717735BEC79Q35779054-6A887A03-B382-4156-93CA-DD588A607F75Q35793345-A06B464D-0371-4349-8820-E439AB6D4D2EQ35868371-6F1288DA-9FBA-43FC-9636-0E164F9FD312Q35936267-6FEF2228-83D2-4AFF-95FD-1A0414BE6973Q35945454-D9BCD7E0-DC3A-41F9-BD13-D7ECC74A9D95Q36040749-2AD105C5-1F70-497A-92D6-B8C0A2E344CCQ36107179-E86FDC8B-A4E4-42A4-B06A-4733404DD3A7Q36165291-3A99E820-25D4-463B-8102-75838A80C34AQ36191044-B3BA9A34-B18C-4229-990D-DD1B4C75F9DAQ36258561-2591BDB0-5CBE-465C-9300-F1ADE0CFA148Q36299177-1F79CE7B-36AD-4729-8016-D8F65CDC8F6AQ36310296-E0DC5AF5-BE59-4EFC-9527-08DC5CC2D9B4Q36310311-BBA0139C-AC9F-4032-91FB-70A777B54398Q36382695-17934D4D-CE20-4403-A915-8035B1CD7F3EQ36577856-6C0E87F7-0D54-4D0B-BB1E-ED985AA51F73Q36929181-AF9FC2B0-070B-4D87-AAA1-7D658ECCF3B4Q36945816-20CDC46E-81DA-44C5-9482-2549B116F39BQ36987106-F203DA14-84B6-4BB8-83D9-604881F92179Q37053637-B4E0B6C9-15AA-44CF-A241-65AC66DB9CA2Q37210118-DA22FD09-C519-438C-A6A4-BD7E4503B21DQ37914103-58FD03D2-2169-4F67-AAE6-F9242F62DA82Q38757870-4085176F-584A-452E-8BB1-B79111B6240EQ39412178-C50B6E1F-9F5C-4D9D-B279-FC0C2F29885EQ40082921-E9EFE190-5E29-4B16-94BC-6B92ADA658EDQ40303946-E4DB5399-1501-4089-803A-D700857BBD52Q40910264-B0C64483-CEE1-4660-B23B-95541E48AEA9Q42781455-26370C80-118D-4CAF-92B6-4509E25D4D87Q44804861-6D634A6A-21BC-4FC2-9DA0-E709043075FAQ46622979-1B27EAC9-DED6-4F92-901C-18D8B3B77F63Q47554728-8625C614-96F7-4C43-A802-C9B995CF0FEDQ47581724-31CF5F96-D5DC-4360-9150-724E61A8F79FQ49775424-C89E31A5-6564-4DF4-A043-10AE608F6F12Q51123490-6DB7CF74-A0CB-4CAF-AAAB-42963CCB3C35Q51978234-EC5F22FE-896E-4D7A-B612-D1C47BED6255Q53698117-A163DF3B-74DD-4BF5-899C-E54B307D8835
P2860
Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Clozapine use in patients with ...... sion: a claims-based approach.
@en
Clozapine use in patients with ...... sion: a claims-based approach.
@nl
type
label
Clozapine use in patients with ...... sion: a claims-based approach.
@en
Clozapine use in patients with ...... sion: a claims-based approach.
@nl
prefLabel
Clozapine use in patients with ...... sion: a claims-based approach.
@en
Clozapine use in patients with ...... sion: a claims-based approach.
@nl
P2093
P1433
P1476
Clozapine use in patients with ...... sion: a claims-based approach.
@en
P2093
P304
P356
10.1001/ARCHPSYC.58.12.1172
P407
P577
2001-12-01T00:00:00Z